WuXi Biologics Hosts Third CRDMO Day in Japan, Accelerating Biopharma Innovation from IND to Commercialization
TOKYO, May 20, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), recently hosted its third CRDMO Day in Tokyo, bringing together senior leaders and experts from...
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
SHANGHAI, May 13, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing...
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
Contributing to the United Nations Sustainable Development Goals, driving equitable access to healthcare through technology and innovation Enhancing governance transparency and effectiveness to create long-term value for all stakeholders Empowering...
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion and key equipment arrival at its microbial...
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5...
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients Zero non-conformities demonstrates company's robust quality management system SHANGHAI, April...
WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year" (Large CDMOs) in the 2026...
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a...
WuXi Biologics Reports Record 2025 Annual Results
Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps) EBITDA rose 38.1% YoY and...
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
SHANGHAI, March 22, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffirms its commitment to sustainability through responsible operations and efficient, circular water‑use practices that reduce environmental impact. WuXi...